User:Fu Hung Shiu/sandbox
Thota Ganesh | |
---|---|
![]() | |
Born | Celina, Ohio, U.S. | May 10, 1970
Education | |
Occupations |
|
Known for | Glutamate receptor biology; neuroinflammation |
Medical career | |
Field | Neuroscience, Neurology |
Institutions | Emory University School of Medicine |
Thota Ganesh(born May 10, 1970) is an Indian-American scientist who has made considerable contributions to the field of organic chemistry and Medicinal chemistry. He serves as associate professor in the School of Medicine at Emory University, Atlanta GA.
Education
[edit]Ganesh grew up in Anantasagar, a village in Telangana, India. He attended obtained Bachler degree in Osmania University, and also got his Master's degree (1994) and Ph.D (1999) in organic chemistry at the same institute. He obtained postdoc training at IIT-Bombay, Durham University (UK), and Virginia Tech (USA) before moving to Emory University (USA)
Career
[edit]Ganesh is an associate professor in the Department of Pharmacology at Emory University. He served in several national and international scientific committees including National Institutes of Health (NIH) grant review committees and served on the scientific review board of ADDF. He co-founded (along with Raymond J. Dingledine and Dennis McNamara) a small pharma company called Pyrefin Inc., in 2019, which develops novel anti-inflammatory drugs to treat memory and cognitive deficits in Epilepsy and other neurodgenerative diseases such as Alzheimer’s disease. He serves on board of Pyrefin, Inc
Research and work
[edit]His early research focused on the modulation of glutamate receptor-mediated synaptic transmission.[1] During this period he and his team discovered that glycine is a coagonist rather than modulator of NMDA receptors,[2] that shrinkage of extracellular space mediates the transition between interictal and ictal states in the high potassium model of seizures,[3][4] that a single amino acid residue controls calcium permeation in glutamate receptor channels,[5] and that ifenprodil analogs inhibit NMDA receptors by increasing the sensitivity of receptors to proton inhibition.[6] His current research focuses on the myriad roles of neuroinflammation in neurologic disorders.[7] He demonstrated a profound role for EP2 receptor activation by prostaglandin E2 in COX-2 related pathologies.[8] His work highlights the importance of neuroinflammation in epilepsy.
Awards and honors
[edit]Dingledine was elected to the US National Academy of Medicine in 2010,[9] the Norwegian Academy of Science and Letters in 2018,[10] and the National Academy of Inventors in 2022.[11] He was elected as a Fellow of American Association for Advancement of Science in 2003, and a Fellow of the American Society for Pharmacology and Experimental Therapeutics in 2020.[12] His early career was profiled in Nature Medicine in 2002.[13] He received the Bristol-Myers Squibb Neuroscience Award in 1989 and again in 1993, the epilepsy basic research award from the American Epilepsy Society in 1995, a Javits Neuroscience Award from the National Institute of Neurological Disorders and Stroke in 1998, the PhRMA Foundation Career Award in Excellence in 1999, and the Robert R Ruffolo Career Achievement Award from the American Society of Pharmacology and Experimental Therapeutics in 2018.[14] Two endowed prizes have been established in his name, the Ray Dingledine Award for Extraordinary Graduate Achievement in 2018[15] and the Ray Dingledine Research Impact Award in Pharmacology & Chemical Biology (2019).[16] In 2023, he is awarded the inaugural AMSPC Award in Pharmacology Research and Administration from the Association of Medical School Pharmacology Chairs (AMSPC).
Personal life
[edit]Dingledine has two sons, Brian and Roger. Dingledine has grown bonsai trees since 1971 and for many years was an avid swimmer with a local Master’s group. He competed in the relay division of the Tugaloo Triathlon and his team (3 Stooges) took first place in 2001, 2003 and 2005,[17] thereby serving as Georgia state champions.
Publications
[edit]Selected papers
[edit]- Kleckner, NW; Dingledine, R (12 August 1988). "Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes". Science. 241 (4867): 835–7. Bibcode:1988Sci...241..835K. doi:10.1126/science.2841759. PMID 2841759.
- McBain, CJ; Traynelis, SF; Dingledine, R (10 August 1990). "Regional variation of extracellular space in the hippocampus". Science. 249 (4969): 674–7. Bibcode:1990Sci...249..674M. doi:10.1126/science.2382142. PMID 2382142.
- Bennett, JA; Dingledine, R (February 1995). "Topology profile for a glutamate receptor: three transmembrane domains and a channel-lining reentrant membrane loop". Neuron. 14 (2): 373–84. doi:10.1016/0896-6273(95)90293-7. PMID 7857646. S2CID 15620279.
- Laezza, F; Doherty, JJ; Dingledine, R (27 August 1999). "Long-term depression in hippocampal interneurons: joint requirement for pre- and postsynaptic events". Science. 285 (5432): 1411–4. doi:10.1126/science.285.5432.1411. PMID 10464102.
- Huang, Y; Myers, SJ; Dingledine, R (October 1999). "Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes". Nature Neuroscience. 2 (10): 867–72. doi:10.1038/13165. PMID 10491605. S2CID 25697585.
- Serrano, GE; Lelutiu, N; Rojas, A; Cochi, S; Shaw, R; Makinson, CD; Wang, D; FitzGerald, GA; Dingledine, R (19 October 2011). "Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus". The Journal of Neuroscience. 31 (42): 14850–60. doi:10.1523/JNEUROSCI.3922-11.2011. PMC 4126152. PMID 22016518.
- Jiang, J; Quan, Y; Ganesh, T; Pouliot, WA; Dudek, FE; Dingledine, R (26 February 2013). "Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation". Proceedings of the National Academy of Sciences of the United States of America. 110 (9): 3591–6. Bibcode:2013PNAS..110.3591J. doi:10.1073/pnas.1218498110. PMC 3587237. PMID 23401547.
- Varvel, NH; Neher, JJ; Bosch, A; Wang, W; Ransohoff, RM; Miller, RJ; Dingledine, R (20 September 2016). "Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus". Proceedings of the National Academy of Sciences of the United States of America. 113 (38): E5665-74. Bibcode:2016PNAS..113E5665V. doi:10.1073/pnas.1604263113. PMC 5035862. PMID 27601660.
- Dingledine, R (September 2018). "Why Is It so Hard to Do Good Science?". eNeuro. 5 (5). doi:10.1523/ENEURO.0188-18.2018. PMC 6126587. PMID 30197928.
- Varvel, NH; Espinosa-Garcia, C; Hunter-Chang, S; Chen, D; Biegel, A; Hsieh, A; Blackmer-Raynolds, L; Ganesh, T; Dingledine, R (3 February 2021). "Peripheral Myeloid Cell EP2 Activation Contributes to the Deleterious Consequences of Status Epilepticus". The Journal of Neuroscience. 41 (5): 1105–1117. doi:10.1523/JNEUROSCI.2040-20.2020. PMC 7880294. PMID 33293358.
- ^ Traynelis, Stephen F.; Wollmuth, Lonnie P.; McBain, Chris J.; Menniti, Frank S.; Vance, Katie M.; Ogden, Kevin K.; Hansen, Kasper B.; Yuan, Hongjie; Myers, Scott J.; Dingledine, Ray (September 2010). "Glutamate Receptor Ion Channels: Structure, Regulation, and Function". Pharmacological Reviews. 62 (3): 405–496. doi:10.1124/pr.109.002451. PMC 2964903. PMID 20716669.
- ^ Kleckner, Nancy W.; Dingledine, Raymond (12 August 1988). "Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes". Science. 241 (4867): 835–837. Bibcode:1988Sci...241..835K. doi:10.1126/science.2841759. PMID 2841759.
- ^ Traynelis, S. F.; Dingledine, R. (1 May 1989). "Role of extracellular space in hyperosmotic suppression of potassium-induced electrographic seizures". Journal of Neurophysiology. 61 (5): 927–938. doi:10.1152/jn.1989.61.5.927. PMID 2723735.
- ^ Traynelis, S. F.; Dingledine, R. (1 January 1988). "Potassium-induced spontaneous electrographic seizures in the rat hippocampal slice". Journal of Neurophysiology. 59 (1): 259–276. doi:10.1152/jn.1988.59.1.259. PMID 3343603.
- ^ Hume, R.; Dingledine, R.; Heinemann, S. (30 August 1991). "Identification of a site in glutamate receptor subunits that controls calcium permeability". Science. 253 (5023): 1028–1031. Bibcode:1991Sci...253.1028H. doi:10.1126/science.1653450. PMID 1653450. S2CID 37111624.
- ^ Mott, David D.; Doherty, James J.; Zhang, Sunan; Washburn, Mark S.; Fendley, Morris J.; Lyuboslavsky, Polina; Traynelis, Stephen F.; Dingledine, Raymond (December 1998). "Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition". Nature Neuroscience. 1 (8): 659–667. doi:10.1038/3661. PMID 10196581. S2CID 2883094.
- ^ Vezzani, Annamaria; Friedman, Alon; Dingledine, Raymond J. (June 2013). "The role of inflammation in epileptogenesis". Neuropharmacology. 69: 16–24. doi:10.1016/j.neuropharm.2012.04.004. PMC 3447120. PMID 22521336.
- ^ Jiang, Jianxiong; Dingledine, Ray (July 2013). "Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection". Trends in Pharmacological Sciences. 34 (7): 413–423. doi:10.1016/j.tips.2013.05.003. PMC 4031445. PMID 23796953.
- ^ "Pharmacology chair elected to the Institute of Medicine". www.emory.edu. Retrieved 4 January 2023.
- ^ "2018 Institute of Basic Sciences - Throne Holst Symposium - Inflammation and Epilepsy – Psychology of Science". Faculty of Medicine. University of Oslo. 2018. Retrieved 4 January 2023.
- ^ "Emory researchers recognized for their spirit of innovation | Emory University | Atlanta GA". news.emory.edu. Retrieved 4 January 2023.
- ^ "2020 Fellows Bios". Default. Retrieved 4 January 2023.
- ^ Birmingham, Karen (1 August 2002). "Ray Dingledine". Nature Medicine. 8 (8): 772. doi:10.1038/nm0802-772. PMID 12152023. S2CID 6731617. Retrieved 27 December 2022.
- ^ "Raymond Dingledine awarded national pharmacology career achievement award | Emory University | Atlanta GA". news.emory.edu. Retrieved 27 December 2022.
- ^ "News from the Office of Development and Alumni Relations". GDBBS Alumni Newsletter. Retrieved 4 January 2023.
- ^ "Department of Pharmacology and Chemical Biology Establishes Ray Dingledine Award for Research Impact | Emory School of Medicine". med.emory.edu. Retrieved 4 January 2023.
- ^ "Active Results". resultscui.active.com. Retrieved 27 December 2022.